Novartis files Tasigna, Aclasta ahead of schedule
This article was originally published in Pharmaceutical Approvals Monthly
Novartis announces the submission of NDAs for the oncologic Tasigna (nilotinib) and osteoporosis therapy Aclasta (zoledronic acid infusion) during its annual pipeline update Nov. 28 in London. The company had been predicting 2007 filings for both applications (1Pharmaceutical Approvals Monthly May 2006, p. 3). The Tasigna application, filed in both the U.S. and Europe, seeks an indication for treatment of chronic myeloid leukemia; Novartis also announced a global nilotinib expanded access program called ENACT that will be available to eligible patients in all phases of Philadelphia chromosome-positive CML who are resistant to or intolerant of Novartis' Gleevec (imatinib). Novartis seeks to differentiate Aclasta in the crowded osteoporosis market with its once-yearly administration and complete range of claims for "vertebral, both clinical and non-clinical vertebral diagnosed by x-ray, as well as hip and non-vertebral sites," Global Pharma Development Head James Shannon told investors...
You may also be interested in...
If J&J’s gamble on a single dose pays off, it could rapidly advance the fight against SARS-CoV2 – but a second study will provide a safety net.
Agency has been prepping Woodcock for the temporary task but what will happen to her role on Operation Warp Speed remains unclear. The move should give Biden team cushion to confirm a permanent leader of whom a top contender is former senior FDA staffer Joshua Sharfstein, a proponent of drug reforms that may irk manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.